RayKnowChina Research Map
Shortlist

Cancer

Breast cancer in Xi'an

西安 乳腺癌

All diseases in Xi'an

8 hospitals in Xi'an

Order: papers led on breast cancer, 2021–2025, then A–Z. Research activity, not a rating of care.

Only hospitals listed for breast cancer: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Xi'an may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.

  1. 133 papers led
    No open trial led
  2. 70 papers led
    No open trial led
  3. 47 papers led
  4. 18 papers led
    No open trial led
  5. 14 papers led
  6. 11 papers led
  7. 0 papers led
    No open trial led
  8. 0 papers led
    No open trial led

Breast cancer in every city Xi'an on the disease page, with the national map

45

open trials on breast cancer with a hospital in Xi'an

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Xi'an as lead sponsor or study site. 11 of them are led by a hospital in Xi'an. Check the registry for the current status. Whether someone can take part is decided by the study team.

Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.

  1. Recruiting
    A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
    Phase
    Not given
    Started
    2026-01
    Posted
    Registry
    NCT07347600

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Weifang, Wuhan, Xi'an, Xiamen, Yangzhou, Zhengzhou

  2. Recruiting
    Study on the Cosmetic Outcome and Safety Evaluation of 3D Printed Biodegradable Biological Mesh for One-Stage Breast Reconstruction After Radical Mastectomy
    Phase
    N/A
    Started
    2026-01
    Posted
    Registry
    NCT07365267

    Age 18 years to 70 years; women only (registered criteria)

    Led by Xijing HospitalXi'an

  3. Recruiting
    Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07383818

    Age 18 years to 70 years; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 4 listed hospitals as study sitesHangzhou, Harbin, Hefei, Shanghai, Xi'an

  4. Recruiting
    BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
    Phase
    Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07492641

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Kunming, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shijiazhuang, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Zhengzhou

  5. Recruiting
    SMP-656 for HER2-Positive Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07726342

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Shenyang, Shijiazhuang, Wuhan, Xi'an, Zhengzhou

  6. Recruiting
    Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT06757634

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Jinan, Luoyang, Nanchang, Nanjing, Ningbo, Shenyang, Tianjin, Weifang, Xi'an, Xinxiang, Yangzhou, Zhengzhou

  7. Recruiting
    A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2025-04
    Posted
    Registry
    NCT06790693

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Kunming, Nanning, Tianjin, Urumqi, Xi'an, Xiangyang

  8. Recruiting
    A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06827236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBengbu, Changchun, Chengdu, Chongqing, Nanning, Shanghai, Xi'an

  9. Recruiting
    A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06841354

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanjing, Nanning, Taiyuan, Taizhou, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  10. Recruiting
    A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
    Phase
    Phase 2/Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06891833

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesAnyang, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Luoyang, Nanchang, Nanning, Shanghai, Shenzhen, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou

  11. Recruiting
    Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT06914440

    Age 18 years to 75 years; women only (registered criteria)

    Led by Xijing HospitalXi'an

  12. Recruiting
    Clinical Efficacy and Safety Assessment of Breast-Conserving Surgery for Central Breast Cancer: A Prospective Randomized Controlled Trial
    Phase
    N/A
    Started
    2025-02
    Posted
    Registry
    NCT06938360

    Age 18 years to 70 years; women only (registered criteria)

    Led by Xijing HospitalXi'an

  13. Recruiting
    A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06966700

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Changchun, Changsha, Hangzhou, Harbin, Hefei, Jinan, Nanjing, Nanning, Shanghai, Urumqi, Wuhan, Xi'an, Xiamen, Zhengzhou

  14. Recruiting
    Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06977893

    Age 18 years to 75 years; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 9 listed hospitals as study sitesHangzhou, Harbin, Hefei, Nanchang, Shanghai, Urumqi, Xi'an, Zhengzhou

  15. Recruiting
    3D-printed Biodegradable Breast Implants for Breast Restoration
    Phase
    Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT06993714

    Age 18 years to 70 years; women only (registered criteria)

    Led by Xijing HospitalXi'an

  16. Recruiting
    A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT07043725

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 52 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Harbin, Hefei, Hengyang, Jinan, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Xinxiang, Yantai, Zhengzhou

  17. Recruiting
    JS207 Combination Therapy in Triple-negative Breast Cancer
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07045311

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changchun, Dalian, Hangzhou, Harbin, Hefei, Nanjing, Qingdao, Shenyang, Shijiazhuang, Urumqi, Wuhan, Xi'an, Zhengzhou

  18. Recruiting
    TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07047365

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 44 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guiyang, Haikou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Luzhou, Nanchang, Nanchong, Nanjing, Nanning, Ningbo, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Tangshan, Tianjin, Weifang, Wenzhou, Xi'an, Xiangyang, Xining, Xinxiang, Xuzhou, Zhengzhou

  19. Recruiting
    A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07060807

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Nanning, Taizhou, Urumqi, Xi'an, Xiamen, Xiangyang, Zhengzhou

  20. Recruiting
    A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
    Phase
    Phase 3
    Started
    2025-08
    Posted
    Registry
    NCT07062965

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Wenzhou, Wuhan, Xi'an

  21. Recruiting
    ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
    Phase
    Phase 3
    Started
    2025-10
    Posted
    Registry
    NCT07173751

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesHefei, Jinan, Lanzhou, Linyi, Nanchang, Taiyuan, Wuhan, Xi'an, Zhengzhou

  22. Recruiting
    A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC
    Phase
    Phase 1
    Started
    2025-11
    Posted
    Registry
    NCT07178171

    Age 18 years to 70 years; women only (registered criteria)

    Led by Xijing HospitalXi'an

  23. Recruiting
    A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2025-01
    Posted
    Registry
    NCT07673029

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 51 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Meizhou, Nanchang, Nanning, Qingdao, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xi'an, Xinxiang, Xuzhou, Yantai, Zhengzhou

  24. Recruiting
    A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
    Phase
    Not given
    Started
    2024-01
    Posted
    Registry
    NCT06210776

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Chengdu, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Kunming, Luoyang, Nanchang, Nanjing, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Taiyuan, Tangshan, Tianjin, Urumqi, Weifang, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou, Zhuhai

  25. Recruiting
    The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06452706

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesHangzhou, Harbin, Shanghai, Urumqi, Wuhan, Xi'an

  26. Recruiting
    Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06682195

    Age 18 years to 70 years; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 10 listed hospitals as study sitesHangzhou, Harbin, Hefei, Nanchang, Shanghai, Taiyuan, Urumqi, Xi'an, Zhengzhou

  27. Recruiting
    Research on the Potential Mechanisms Underlying the Efficacy Differences in Specific Neoadjuvant Treatment Regimens for Different Subtypes of Breast Cancer
    Phase
    N/A
    Started
    2024-04
    Posted
    Registry
    NCT07012720

    Age 25 years to 75 years; women only (registered criteria)

    Led by Xijing HospitalXi'an

  28. Recruiting
    Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
    Phase
    Phase 3
    Started
    2023-10
    Posted
    Registry
    NCT05696626

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 57 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Kunming, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  29. Recruiting
    Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
    Phase
    Phase 2/Phase 3
    Started
    2023-09
    Posted
    Registry
    NCT05860465

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Luoyang, Nanjing, Shenyang, Shijiazhuang, Tianjin, Xi'an, Yinchuan

  30. Recruiting
    Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
    Phase
    Phase 3
    Started
    2023-06
    Posted
    Registry
    NCT05891093

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 13 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nantong, Ningbo, Shanghai, Shenyang, Xi'an, Yangzhou

  31. Recruiting
    Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
    Phase
    Phase 3
    Started
    2023-06
    Posted
    Registry
    NCT05909332

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 13 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nantong, Ningbo, Shanghai, Shenyang, Xi'an, Yangzhou

  32. Recruiting
    Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT05950945

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Fuzhou, Hangzhou, Hefei, Jinan, Kunming, Nanchang, Qingdao, Shanghai, Xi'an, Zhengzhou

  33. Recruiting
    JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06079983

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 60 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Hengyang, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Meizhou, Nanchang, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xining, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi

  34. Recruiting
    A Study of YL202 in Selected Patients With Advanced Solid Tumors
    Phase
    Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06107686

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jinan, Meizhou, Nanchang, Nanning, Qingdao, Shanghai, Shantou, Shenyang, Suzhou, Taiyuan, Taizhou, Urumqi, Weifang, Wuhan, Xi'an, Xiangyang, Xuzhou, Zhengzhou

  35. Recruiting
    Assessment of Brain Cognitive Impairment in Breast Cancer
    Phase
    Not given
    Started
    2022-05
    Posted
    Registry
    NCT05305092

    Age not stated; women only (registered criteria)

    Led by Tangdu HospitalXi'an

  36. Recruiting
    A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2022-01
    Posted
    Registry
    NCT05851014

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesBengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an, Yinchuan, Zhengzhou

  37. Recruiting
    Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
    Phase
    Phase 4
    Started
    2021-06
    Posted
    Registry
    NCT04790305

    Age 18 years to 70 years (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 26 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Wuhan, Xi'an, Yangzhou, Zhengzhou

  38. Recruiting
    Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
    Phase
    Phase 2
    Started
    2020-09
    Posted
    Registry
    NCT04557449

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Wuhan, Xi'an, Zhengzhou

  39. Recruiting
    Study of PF-07248144 in Advanced or Metastatic Solid Tumors
    Phase
    Phase 2
    Started
    2020-11
    Posted
    Registry
    NCT04606446

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Xi'an

  40. Not yet recruiting
    Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07466303

    Age 18 years to 70 years; women only (registered criteria)

    Led by Xijing HospitalXi'an

  41. Not yet recruiting
    A Study of T-DXd in AI-Assessed HER2-Ultralow Metastatic Breast Cancer
    Phase
    N/A
    Started
    2026-09
    Posted
    Registry
    NCT07782086

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Chengdu, Hefei, Luzhou, Nanjing, Shanghai, Xi'an, Xuzhou

  42. Not yet recruiting
    Cohort Study on Sequential ADC Therapy in HR-positive/HER2-negative Advanced Breast Cancer
    Phase
    Phase 4
    Started
    2025-10
    Posted
    Registry
    NCT07162259

    Age 18 years to 85 years; women only (registered criteria)

    Led by Xi'an International Medical Center HospitalXi'an

  43. Not yet recruiting
    A Randomized Controlled Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined with Systemic Therapy for Early-stage Breast Cancer
    Phase
    Phase 2/Phase 3
    Started
    2024-12
    Posted
    Registry
    NCT06769919

    Age 18 years to 65 years; women only (registered criteria)

    Led by Xijing HospitalXi'an

  44. Not yet recruiting
    Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis
    Phase
    N/A
    Started
    2023-09
    Posted
    Registry
    NCT06015113

    Age 18 years to Not stated; women only (registered criteria)

    Led by Xi'an International Medical Center HospitalXi'an

  45. Enrolling by invitation
    A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07376629

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesAnyang, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanjing, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Disease research in Xi'an

Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.

A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.

Papers led and open trials led by hospitals in Xi'an, by disease
CancerBlood disordersOther diseases
HospitalNasopharyngeal carcinomaOesophageal squamous cell carcinomaHepatocellular carcinomaStomach cancerLung cancerPancreatic cancerBreast cancerGliomaHepatoblastomaRetinoblastomaChordomaOsteosarcomaGastrointestinal stromal tumourNeuroblastomaEwing sarcomaMultiple myelomaB-cell acute lymphoblastic leukaemiaAplastic anaemiaHaemophagocytic lymphohistiocytosisLymphomaBeta thalassaemiaHaemophilia AAtypical haemolytic uraemic syndromeThrombotic thrombocytopenic purpuraFanconi anaemiaNeuromyelitis optica spectrum disorderIgG4-related diseaseMyasthenia gravisMoyamoya diseaseWilson diseaseBiliary atresiaCoronary heart diseaseCongenital heart diseaseScoliosisAnti-NMDA receptor encephalitisTakayasu arteritisHepatic echinococcosisIdiopathic pulmonary fibrosisLymphangioleiomyomatosisAmyotrophic lateral sclerosisSpinal muscular atrophyFabry diseasePompe diseaseDuchenne muscular dystrophyBehçet diseaseAlport syndromeIgA nephropathyGaucher diseaseNiemann–Pick disease type COsteogenesis imperfectaPrimary biliary cholangitisPrimary sclerosing cholangitisCongenital diaphragmatic herniaHirschsprung diseaseInherited epidermolysis bullosaHereditary angioedemaFamilial adenomatous polyposisLeber hereditary optic neuropathyMajeed syndromeNGLY1 deficiencyISG15 deficiencyShortlist
Affiliated Hospital of Northwest University西安市第三医院nonenonenonenonenonenonenonenonenonenonenonenonenone3nonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Daxing Hospital西安大兴医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Affiliated Hospital of Fourth Military Medical Universitynonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Affiliated Hospital of the Fourth Military Medical Universitynonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院6121 open1221 open691 open161601336304none233080none1132 opennone10nonenonenonenonenonenonenonenone352 open100none208none3none0nonenone0none7nonenonenone2nonenonenonenonenone1nonenonenonenone
First Affiliated Hospital of Xi'an Medical College西安医学院第一附属医院nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Gao Xin Hospital西安高新医院nonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Honghui Hospital西安市红会医院nonenonenonenonenonenonenonenonenonenone020none1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone3nonenonenone1none2nonenonenonenonenonenone1nonenonenonenone1nonenonenonenonenonenonenonenonenone
Northwest Women's Hospital西北妇女儿童医院nonenonenonenonenonenonenonenone00nonenonenone0nonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine陕西中医药大学第二附属医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Second Affiliated Hospital of Xi'an Jiaotong University西安交通大学第二附属医院none12572075207012none218none011700none7nonenonenonenonenonenonenonenonenonenonenone640nonenonenone4nonenone41none11none2nonenonenone22none5none0nonenonenonenonenone
Second Affiliated Hospital of Xi'an Medical College西安医学院第二附属医院nonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shaanxi Province Hospital陕西省中医医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shaanxi Provincial People's Hospital陕西省人民医院none3none27nonenone18nonenone0none2none2none3nonenonenonenonenonenonenonenonenonenonenonenonenonenonenone161 open3nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Tangdu Hospital空军军医大学唐都医院none137 open16141 open6911 open10141 open2911none5nonenonenonenonenonenone28nonenonenonenonenone53 opennone203 opennonenonenone7nonenone1002nonenonenonenonenonenonenonenone0nonenonenone0nonenone0nonenonenonenonenonenonenone
University Medical College First Affiliated Hospitalnonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone3nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Xi'an Chest Hospital西安市胸科医院nonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Xi'an Children's Hospital西安市儿童医院nonenonenonenonenonenonenone71112none30nonenonenonenonenonenonenonenonenonenonenonenonenonenonenone3none5none1nonenone1nonenonenone021none00nonenonenonenonenonenone1nonenonenonenonenonenonenone
Xi'an First Hospital西安市第一医院nonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Xi'an Hospital西安市中医医院nonenonenonenonenonenonenonenonenone11nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Xi'an International Medical Center Hospital西安国际医学中心医院nonenonenonenonenonenone112 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenone
Xi'an Ninth Hospital西安市第九医院nonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Xi'an People's Hospital西安市人民医院(西安市第四医院)nonenonenonenonenonenonenonenonenone3none1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Xian Central Hospital西安市中心医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Xian XD Group Hospital西电集团医院nonenonenonenonenonenonenonenonenonenonenone0none0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Xijing Hospital空军军医大学西京医院51 open2258627 open321 open102 open478 open461 open1none11842221nonenone6nonenonenone1nonenone1none2nonenone425 open6533none1nonenonenonenonenone01none1001none176 open1nonenonenonenone0nonenonenonenone

Column labels are short names. Choose one to open that disease in Xi'an.

Other cities nearby

Straight-line distance from the city centre; counts are hospitals listed for breast cancer.

Counts are listed hospitals only, not every hospital in each city.

Where these numbers come from

Papers

English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions

Trials

ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Xi'an on ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data